APA (7th ed.) Citation

Y, Y., Y, Y., VJ, S., AB, D., CL, E., A, D., . . . MS, B. (2025). Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma. Frontiers in immunology, 16, 1491448. https://doi.org/10.3389/fimmu.2025.1491448

Chicago Style (17th ed.) Citation

Y, Yao, et al. "Phase I Study of Pembrolizumab in Combination with Ibrutinib for the Treatment of Unresectable or Metastatic Melanoma." Frontiers in Immunology 16 (2025): 1491448. https://doi.org/10.3389/fimmu.2025.1491448.

MLA (9th ed.) Citation

Y, Yao, et al. "Phase I Study of Pembrolizumab in Combination with Ibrutinib for the Treatment of Unresectable or Metastatic Melanoma." Frontiers in Immunology, vol. 16, 2025, p. 1491448, https://doi.org/10.3389/fimmu.2025.1491448.